COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Antibodies, Monoclonal, Humanized
/ therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Humans
Immunologic Factors
/ therapeutic use
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive
/ complications
Pandemics
Pneumonia, Viral
/ complications
Protective Factors
SARS-CoV-2
Severity of Illness Index
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
07
04
2020
accepted:
09
04
2020
pubmed:
22
4
2020
medline:
3
7
2020
entrez:
22
4
2020
Statut:
ppublish
Résumé
Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19. In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19. Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred. This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19.
METHODS
METHODS
In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19.
RESULTS
RESULTS
Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred.
DISCUSSION
CONCLUSIONS
This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients.
Identifiants
pubmed: 32315980
pii: S2211-0348(20)30197-8
doi: 10.1016/j.msard.2020.102120
pmc: PMC7156942
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immunologic Factors
0
ocrelizumab
A10SJL62JY
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
102120Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest Giovanni Novi received speaker honoraria from Merck, Novartis and Roche Malgorzata Mikulska received speaker honoraria from MSD, Gilead, Pfizer, Biotest, Janssen; all outside the submitted work. Federica Briano reports no disclosures Federica Toscanini reports no disclosures Francesco Tazza reports no disclosures Antonio Uccelli: received honoraria or consultation fees from Biogen, Roche, Teva, Merck-Serono, Genzyme, Novartis Matilde Inglese received honoraria or consultation fees from Roche, Biogen, Merck-Serono, Genzyme and research grants from NIH, NMSS, FISM, Novartis and Teva Neuroscience
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578